Company Overview

Arrayit Corporation (OTC: ARYC) was a U.S.-based biotechnology and life sciences company focused on diagnostic testing, microarray technologies, and personalized medicine applications. The company developed and marketed proprietary protein and DNA microarray platforms used for clinical diagnostics, research, and laboratory testing services. Its operations historically centered on blood-based diagnostic testing, allergy testing, and molecular diagnostics, with an emphasis on early disease detection and precision medicine applications.

The company evolved from earlier microarray and genomics research initiatives and became known for its patented microarray instrumentation and assay technologies. Arrayit positioned itself as a developer of integrated diagnostic systems combining laboratory services with proprietary hardware and consumables. Public disclosures and market reports indicate the company attempted to expand into large-scale clinical testing and personalized healthcare markets; however, publicly available operational and financial information became increasingly limited in later years. Regulatory filings and trading disclosures indicate substantial uncertainty regarding the company’s operational status and reporting compliance.

Business Operations

Arrayit generated revenue historically through laboratory testing services, diagnostic assays, and sales or licensing of proprietary microarray technologies. Its principal business activities included molecular diagnostics, allergy testing, autoimmune testing, and related laboratory services conducted through its CLIA-certified laboratory operations. The company also promoted proprietary instruments, assay platforms, and consumable products associated with its microarray technologies. Key operating activities were concentrated in the United States, particularly within California-based laboratory and research facilities.

The company’s business structure included diagnostic service operations and intellectual property tied to microarray technologies. Arrayit publicly referenced collaborations and relationships with healthcare providers, laboratories, and research organizations, although detailed current partnership information is limited in recent public disclosures. Data concerning active subsidiaries, joint ventures, and continuing commercial operations is inconclusive based on available public sources. Public filings and OTC market disclosures also indicate periods of delinquent reporting and reduced financial transparency.

Strategic Position & Investments

Arrayit’s strategic direction historically focused on expanding precision diagnostics and leveraging proprietary microarray technologies for broader clinical adoption. The company emphasized blood-based testing platforms intended to support personalized medicine, early disease detection, and high-throughput laboratory diagnostics. It also promoted the scalability of its microarray systems for healthcare and research applications, seeking differentiation through integrated testing platforms and intellectual property assets.

Public statements and historical investor materials referenced investments in diagnostic assay development, laboratory infrastructure, and commercialization initiatives. The company also highlighted opportunities in autoimmune disease diagnostics, allergy testing, and molecular medicine. However, independently verifiable information regarding recent acquisitions, active investment programs, or material strategic expansion initiatives remains limited. Data concerning current operating investments, portfolio holdings, or emerging technology deployments is inconclusive based on available public sources.

Geographic Footprint

Arrayit’s operations were primarily based in the United States, with headquarters and laboratory activities historically located in California. The company marketed its diagnostic technologies and laboratory services domestically and, according to prior company materials, sought international commercial opportunities through distribution relationships and research collaborations.

Publicly available information does not indicate a significant multinational operational infrastructure comparable to larger biotechnology firms. While the company referenced international interest in its technologies, verifiable evidence of substantial long-term operational presence across multiple continents is limited. Data concerning current international operations or foreign investment influence is inconclusive based on available public sources.

Leadership & Governance

Arrayit was founded and led for many years by Mark Schena, a scientist associated with early microarray technology development. Public records, regulatory proceedings, and company disclosures identified him as a central executive figure in the company’s strategy and commercialization efforts. The company’s leadership approach emphasized innovation in diagnostic testing and the integration of genomic technologies into clinical healthcare applications.

Key executives and leadership figures publicly associated with Arrayit included:

• Mark Schena – President and Chief Executive Officer
• Rene Schena – Corporate Secretary and executive leadership roles referenced in company disclosures

Public regulatory records indicate the company faced governance, compliance, and reporting challenges during later periods of operation. Certain leadership and operational details could not be independently verified through recent audited filings.